Irinotecan-induced muscle twitching from a possible drug interaction: A case report

Abstract

We report the case of a 50-year-old human immunodeficiency virus-positive patient with stage IV KRAS-mutated colorectal cancer who experienced visible muscle twitching in the right lateral triceps brachii from irinotecan administration for which typical supportive care measures were unsuccessful, including the administration of atropine and slowing down the infusion rate. The patient was able to tolerate this reaction and received 20 cycles of irinotecan-based chemotherapy despite experiencing the muscle twitching with every cycle at the same onset, duration, and severity. It is possible that competitive metabolism by concomitant medications metabolized by CYP3A4 or UGT1A1 was responsible for this event. Due to ethical concerns, we were unable to formally assess the drug interaction by discontinuing the suspected interacting medications and re-initiating them to evaluate the effects. A formal pharmacokinetic study may be warranted to better elucidate these potential drug interactions.

Keywords

Drug interaction irinotecan raltegavir UGT1A1 cytochrome P450 3A4

Get full access to this article

View all access options for this article.

References

Mathijssen

Loos

Verweij

et al.

Pharmacology of topoisomerase I inhibitors irinotecan (CPT-11) and topotecan. Curr Cancer Drug Targets 2002; 2: 103–123.

Santos

Zanetta

Cresteil

et al.

Metabolism of irinotecan (CPT-11) by CYP3A4 and CYP3A5 in humans. Clin Cancer Res 2000; 6: 2012–2020.

Naranjo

Busto

Sellers

et al.

A method of estimating the probability of adverse drug reactions. Clin Pharmacol Ther 1981; 30: 239–245.

Chandar

Marsh

. Severe generalized weakness, paralysis, and aphasia following administration of irinotecan and oxaliplatin during FOLFIRINOX chemotherapy. Case Rep Oncol 2015; 8: 138–141.

Ramirez

Koch

Edenfield

. Irinotecan-induced dysarthria: a case report and review of the literature. J Oncol Pharm Pract 2017; 23: 226–230.

Gomez

Sanchez

Ramirez

. Irinotecan-induced dysarthria: an insight into its pathogenesis? Gastrointest Cancer Res 2008; 2: 209–210.

Hamburg

De Jong

Brandsma

et al.

Irinotecan-induced central nervous system toxicity. Report on two cases and review of the literature. Acta Oncol 2008; 47: 974–978.

Lee

Kang

Ahn

et al.

Dysarthria induced by irinotecan in a patient with colorectal cancer. Am J Health Syst Pharm 2013; 70: 1140–1143.

Iyer

King

Whitington

et al.

Genetic predisposition to the metabolism of irinotecan (CPT-11). Role of uridine diphosphate glucuronosyltransferase isoform 1A1 in the glucuronidation of its active metabolite (SN-38) in human liver microsomes. J Clin Invest 1998; 101: 847–854.

10.

Khrer

Mathijssen

Verweij

et al.

Modulation of irinotecan metabolism by ketoconazole. J Clin Oncol 2002; 20: 3122–3129.

11.

Mannheimer

von Bahr

Pettersson

et al.

Impact of multiple inhibitors or substrates of cytochrome P450 2D6 on plasma risperidone levels in patients on polypharmacy. Ther Drug Monit 2008; 30: 565–569.

12.

Wang

Guo

et al.

Clinical significance of UGT1A1 gene polymorphisms on irinotecan-based regimens as the treatment in metastatic colorectal cancer. Onco Targets Ther 2014; 7: 1653–1661.

13.

Elens

van Gelder

Hesselink

et al.

CYP3A4*22: promising newly identified CYP3A4 variant allele for personalizing pharmacotherapy. Pharmacogenomics 2013; 14: 47–62.

14.

Evaluation of Genomic Applications in Practice and Prevention (EGAPP) Working Group. Recommendations from the EGAPP Working Group: can UGT1A1 genotyping reduce morbidity and mortality in patients with metastatic colorectal cancer treated with irinotecan? Genet Med 2009; 11: 15–20.

15.

Araki

Ishikawa

Iigo

et al.

Relationship between development of diarrhea and the concentration of SN-38, an active metabolite of CPT-11, in the intestine and the blood plasma of athymic mice following intraperitoneal administration of CPT-11. Jpn J Cancer Res 1993; 84: 697–702.

16.

Abigerges

Chabot

Armand

et al.

Phase I and pharmacologic studies of the camptothecin analog irinotecan administered every 3 weeks in cancer patients. J Clin Oncol 1995; 13: 210–221.

17.

Baugh

Basura

Ishii

et al.

Clinical practice guideline: Bell's Palsy executive summary. Otolaryngol Head Neck Surg 2013; 149: 656–663.